All the news Showing 10 of 21 articles from: New and experimental treatments for hepatitis BGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Gilead immune modulator has modest effect on hepatitis B surface antigen Keith Alcorn / 01 September 2020 Selgantolimod, a toll-like receptor agonist designed to enhance immune responses to hepatitis B virus, showed only modest effects on hepatitis B surface antigen levels in a phase 2 safety and efficacy study presented ... JNJ-3989 achieves sustained reductions in hepatitis B surface antigen Keith Alcorn / 29 August 2020 Johnson & Johnson’s short interfering RNA treatment for hepatitis B resulted in sustained reductions in hepatitis B surface antigen when combined with nucleoside analogue drugs, Professor Edward Gane of Auckland City Hospital, New ... GSK antisense agent for hepatitis B shows promise Keith Alcorn / 29 August 2020 An antisense agent, GSK-3228836, significantly reduced hepatitis B surface antigen levels in previously untreated people with chronic hepatitis B after three injections, an early phase trial reported this week at the Digital International ... Phase 1 clinical study begins for VTP-300 Immunotherapeutic for Hepatitis B patients Express Healthcare / 14 July 2020 Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection Assembly Biosciences press release / 14 July 2020 Gilead axes $445M Precision Biosciences gene therapy hep B pact Fierce Biotech / 14 July 2020 Vir's hep B drug, poised for combo trials, shows promise in phase 2 Fierce Biotech / 28 April 2020 Hepatitis B Foundation Plans Externally-Led Patient-Focused Drug Development Meeting for Chronic Hepatitis B in June 2020 Hepatitis B Foundation / 11 December 2019 Therapeutic hepatitis B vaccine may lead to functional cure Liz Highleyman / 13 November 2019 An experimental therapeutic vaccine called NASVAC, which targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen (HBsAg) levels, according to study presented this week ... Roche takes aim at hepatitis B, striking R&D deal with Dicerna Biopharma Dive / 12 November 2019 ← First123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds